Johnson & Johnson (NYSE:JNJ) EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of JNJ opened at $146.84 on Friday. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The business’s fifty day moving average is $144.06 and its 200 day moving average is $144.13. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. The stock has a market cap of $386.60 billion, a P/E ratio of 21.47, a P/E/G ratio of 3.25 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business’s revenue was down 10.8% compared to the same quarter last year. During the same period last year, the firm posted $2.58 EPS. On average, analysts expect that Johnson & Johnson will post 7.85 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Orser Capital Management LLC boosted its position in shares of Johnson & Johnson by 44.2% during the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock valued at $272,000 after purchasing an additional 575 shares in the last quarter. Franklin Resources Inc. increased its position in Johnson & Johnson by 11.6% in the fourth quarter. Franklin Resources Inc. now owns 12,626,462 shares of the company’s stock worth $1,841,810,000 after buying an additional 1,311,739 shares in the last quarter. Vigilare Wealth Management purchased a new stake in Johnson & Johnson in the fourth quarter worth about $1,917,000. GW Henssler & Associates Ltd. increased its position in Johnson & Johnson by 3.3% in the fourth quarter. GW Henssler & Associates Ltd. now owns 2,935 shares of the company’s stock worth $428,000 after buying an additional 94 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $320,000. Hedge funds and other institutional investors own 68.44% of the company’s stock.
A number of equities research analysts have recently issued reports on JNJ shares. Citigroup boosted their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $168.00 target price on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Raymond James boosted their target price on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Barclays upped their price objective on shares of Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Finally, Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $163.38.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is the Producer Price Index (PPI)?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.